Breathe Well Live Well
|
New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA …
News-Medical.net These were the main findings from a new subset of data from the Phase III UniTinA-asthma® programme presented for the first time today at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic …
PR Newswire (press release) SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ — Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San … |
View full post on asthma – Google News
|
New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on …
News-Medical.net New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for … BOEHRINGER INGELHEIM GMBH : Key results from new tiotropium studies in … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
PR Newswire (press release) Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma™ is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult … Promising Phase II Data With Once-Daily Tiotropium may Lead to New Treatment … Results of Phase II Study of Boehringer Ingelheim's Investigational … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
MarketWatch (press release) Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma(TM) is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult … Boehringer Ingelheim Announces Positive Phase II Results for Once-Daily … Results of Phase II Study of Boehringer Ingelheim's Investigational … |
View full post on asthma – Google News